Administration Of Third-Party Virus-Specific T-Cells (Vst) At The Time Of Initial Therapy For Infection After Haemopoietic Stem Cell Transplant Is Safe And Associated With Favourable Clinical Outcomes (The R3act-Quickly Trial)
BLOOD（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要